Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Diabodies act as guided missiles targeted to mammary tumor growth

02.09.2004


A mini-antibody bearing a payload of tumor-busting radiation thwarts the growth of human breast cancer in laboratory animals, according to research published in the September 1 issue of the journal Cancer Research.

The research shows that a diabody, an antibody surrogate just one third the size of native antibodies, can be used effectively as a targeting vehicle for radioimmunotherapy, said Gregory Adams, Ph.D., associate member of the Medical Science Division, Fox Chase Cancer Center, Philadelphia, Pa.

Diabodies are genetically engineered dimeric proteins produced in E. coli bacteria that contain the antigen-recognizing portion of antibodies formed by immune system cells to combat disease. The mini-antibody developed by Adams and colleagues, C6.5K-A, is a protein substitute for larger, naturally produced antibodies that specifically target the HER2/neu human tumor-associated antigen. When loaded with the beta-emitting radioisotope yttrium-90, C6.5K-A significantly inhibits the growth rate of human breast tumor xenografts in mice. "The diabodies bound to the HER2 receptor produced by certain breast tumor cells." said Adams, the lead author on the paper. "Imaging indicated that the diabody was concentrated in the mammary tumors and in the kidney where it was excreted from the body."



Since diabodies are so much smaller than native antibodies, the genetically engineered protein is cleared much quicker from the body, Adams said. However, the affinity that the diabody has for its antigen target is so great that a significant amount of the cell-killing radioactive protein lodges in the mammary tumor cells. "The dimeric C6.5K-A binds to its target antigen 40 times more tenaciously than its individual monomeric components, thus promoting prolonged retention in antigen-laden tumors. At the same time, its small size enables it to efficiently find and penetrate these tumors," Adams said.

Using the HER2 receptor protein on tumor cell membranes as a portal into the cells, the radioactive diabody gained access inside tumors to induce cell death and restrict tumor growth.

Although radioactive C6.5K-A was effective against the human mammary tumors growing in mice, the biotherapeutic fell short of inhibiting human ovarian tumor cell growth in the lab animals. "The kinetics of the HER2 receptor on the mammary tumor cells are favorable to taking up the diabody," Adams said. "Once the beta-emitter is delivered inside the mammary tumor cells, the radiation causes intracellular damage that probably triggers p53 driven apoptosis."

The mammary tumor cells contained the normally functioning p53 tumor suppressor gene, while the p53-null ovarian tumor cells used in the studies lacked the protective action of that apoptosis-inducing gene. The mammary tumor cells also internalized the HER2-bound diabody fifteen times more rapidly than did the ovarian tumor cells.

Ongoing studies by Adams and his colleagues are aimed at determining refinements in the radioisotope-bearing diabody that will optimize tumor growth inhibition or reduce tumor mass while preserving the health and function of kidneys.

Russell Vanderboom, PhD | EurekAlert!
Further information:
http://www.aacr.org

More articles from Life Sciences:

nachricht What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>